【Aoki Drug】Executive Changes and Strengthening of Medium-Term Management Plan｜July 2026

Overview of Executive Personnel Changes

This document announces that Aoki Drug Holdings Co., Ltd. has decided on the appointment of new director candidates, outside director candidates, and substitute auditor candidates in preparation for the shareholders' meeting on August 19, 2026. Four individuals—Takeshi Yoshida, Yosuke Enkado, Minoru Ozawa, and Shinichi Morioka—have been newly nominated as officer candidates, with some officers scheduled to retire. These personnel changes are aimed at achieving the financial targets of the company's Fourth Medium-Term Management Plan and enhancing governance. In particular, candidates with extensive experience and expertise are being appointed to accelerate management decision-making and improve supervisory functions.

Future Outlook and Corporate Strategy

With the appointment of new officers, the company aims for sustainable growth and improved capital efficiency by strengthening its earnings structure and actively promoting M&A activities. The company expects to receive advice and oversight from a neutral standpoint independent of the management team, contributing to increased transparency in governance. Through these efforts, the company plans to pursue more solid management toward achieving sales and profit targets.